reflection in the waveguides), and the device allows the authors to identify the type of polarization entanglement carried by the pair of photons (Fig. 1) .
. However, in all of these demonstrations, the quantum information carried by the photons has been path encoded -that is, a photon in one waveguide is used to encode a logical bit 0, with a photon in a second waveguide encoding a logical bit 1. This path encoding is incompatible with the commonly used and very convenient polarization encoding -for example, horizontal photon polarization for a 0 and vertical polarization for a 1. Using polarization encoding in waveguides is not straightforward because the speed with which these two polarizations of light propagate is typically slightly different owing to an effect called birefringence, which is caused by the geometry and/or the materials from which the waveguides are made. This birefringence changes the polarization state of photons propagating in the waveguide, from diagonal to circular for example, and can ultimately depolarize the photons, limiting their capacity to interfere and leading to a loss of information.
An alternative approach to constructing waveguides, used by Sansoni et al. 1 , involves tightly focusing a powerful pulsed laser beam onto a material such as glass and so permanently changing the material's properties to create a waveguide. By scanning the position of the focused spot around the sample, waveguides can be directly written in all three dimensions of the sample. Quantum photonic circuits with circular waveguides 11 have been made in this way -suggesting that the waveguides would exhibit low birefringence and be able to support polarization encoding. In their study, Sansoni et al. 1 demonstrate that the approach can indeed lead to waveguides that support polarization encoding.
They used the technique to fabricate two waveguides on a glass chip and bring them into close proximity, so making a device -termed a directional coupler -that acts like a beamsplitter: it reflects half of the incident light and transmits the other half. When an entangled pair of photons was launched into the two waveguides, the symmetry of the entanglement injected into the device -technically called 'singlet' or 'triplet' states -could be determined. This is because the singlet state 'anti-bunches' at the coupler such that the photons come out of each output waveguide separately, whereas the triplet states 'bunch' such that both photons come out in the same waveguide (Fig. 1) .
This polarization-compatible approach to on-chip integrated quantum photonics holds great potential for being combined with the standard methods for generating and measuring photonic entanglement. As the authors 1 point out, it should make the implementation of sophisticated multi-photon quantum circuits such as entanglement filters 12 , and even more advanced circuits, much more straightforward. However, integrated devices that can perform polarization rotations in analogy with their bulk optical counterparts -'integrated waveplates' -will ultimately be crucial, as will a path to miniaturizing these circuits further to make large quantum photonic circuits possible. 
Recollection of lost memories
With age comes wisdom, or so they say. The reality is that, with age, the ability to store memories declines. One way of tackling this problem might be to raise neuronal levels of the signalling molecule EphB2. See Article p.47 r o B e r T C . M a l e n k a & r o B e r To M a l i n o W W here did I put those keys? What did I have for dinner last night? Cognition -most notably, the ability to store memories -inevitably declines with age. What's more, for an increasing proportion of individuals, this decline progresses aggressively to the point that they cannot care for themselves. Alzheimer's disease is the leading cause of such dementia in the elderly, affecting almost 50% of people over the age of 85. But despite considerable progress in understanding the biology of this disease, an effective treatment remains elusive. On page 47 of this issue, Cissé et al. 1 provide compelling evidence that manipulation of a specific membrane protein -the receptor tyrosine kinase EphB2 -in a mouse model of Alzheimer's disease can reverse the characteristic memory deficits and so may make for a promising therapeutic strategy.
The leading hypothesis for the cause of Alzheimer's disease -based initially on human genetic findings, and supported by many cellbiological, animal-model and human studies -is chronically high brain levels of a peptide fragment termed Aβ. Indeed, mutations in the enzymes that generate Aβ or in the Aβ precursor protein, which lead to increased Aβ levels, are associated with early-onset Alzheimer's 2, 3 . Mice genetically engineered to express these same mutations develop cognitive deficits as they age 2, 3 . In normal mice, meanwhile, raising neuronal Aβ levels causes a loss of synaptic junctions between these cells that correlates well with the degree of dementia in humans. Furthermore, Aβ can now be imaged non-invasively in the human brain, and brain images of patients with Alzheimer's disease show Aβ accumulation, the extent of which correlates with memory decline 4 . Thus, there is great motivation to determine how Aβ accumulation leads to memory impairment.
Learning and memory are thought to require T h o M a s C a r e l l T he DNA molecule, which encodes the complexity of all life forms on Earth, is arguably the most powerful medium known for data storage and processing. Yet, to date, DNA has found little use in computing applications. Reporting in Angewandte Chemie, Park et al. 1 describe a way in which the molecule of life can be turned into devices able to perform logical operations.
The basis of contemporary computers is Boolean logic, a system in which a 'gate' unit converts input signals into a defined output. The gates have names such as AND, OR and YES, to describe the kind of output that is generated in response to different inputs. Because the output of one gate can be the input of the next gate, hierarchical Boolean networks can be established to compute answers to complex questions. In silicon-based computers, gates are implemented electronically using transistors, which are assembled into integrated circuits. Park et al. 1 , however, have constructed logic gates from DNA. They have used DNA replication as the output signal and built control units into the gates to switch replication on or off depending on specific inputs.
DNA replication is a complex process in which the DNA polymerase enzyme makes duplicates of each strand of a template DNA, starting from two smaller single strands that act as 'primers' (Fig. 1) . These primers must bind tightly to complementary sequences at the ends of the template DNA strands to allow replication. Park et al. 1 used modified DNA primers as the basis of their logic gatesprimers in which a single DNA base had been changed, so that the substitute base could no longer pair up with the complementary base in the DNA template. The presence of such a mismatch prevents the primer from initiating DNA replication. So far, so good. But the long-term potentiation (LTP) of transmission at synapses -a form of plasticity that occurs prominently in the hippocampus region of the brain. The hippocampus is not only required for memory formation, but is also affected early on during Alzheimer's disease 2, 3, 5 . It is perhaps not surprising, therefore, that hippocampal LTP is also impaired in mouse models of the disease and after Aβ application 2, 3 . But the detailed molecular mechanisms that underlie the impairments in LTP and memory in models of Alzheimer's disease are unknown. More importantly, reversing these impairments has proved very difficult.
To make headway on these problems, Cissé et al. 1 examine the mechanisms behind the loss of a crucial synaptic protein complex, the NMDA receptor (NMDAR). This receptor is required for triggering LTP and for hippocampus-dependent memory formation 5 , so it makes sense that its loss and malfunction would contribute to the symptoms of Alzheimer's disease. Indeed, previous studies have found that Aβ both reduces the synaptic function of NMDARs 6 and triggers their internalization from the cell surface 7 . Cissé and colleagues focus on EphB2. This protein interacts with NMDARs 8 , and its deficiency reduces LTP 9, 10 . The authors find that Aβ binds to EphB2, decreasing its levels. What's more, the effects of reducing EphB2 levels in the dentate gyrus -the input region of the hippocampus -in the normal mouse brain mimic the reduced synaptic NMDARs and LTP that occur in an Alzheimer's disease mouse model. These findings lay the foundation for the key question: can virus-mediated expression of EphB2 in the dentate gyrus of an Alzheimer's mouse model overcome the associated synaptic and memory deficits? Remarkably, Cissé et al. report that this manipulation 'cures' the mice, with both NMDAR-mediated synaptic responses and LTP returning to normal levels. Of greatest clinical relevance, however, is the authors' finding that EphB2 expression allows the Alzheimer's mice to learn and remember normally in three different behavioural tasks that test hippocampus-dependent memory.
Cissé and co-workers' observations provide compelling evidence that EphB2 may be a valuable target for the treatment of Alz heimer's disease. The authors point out several ways by which treatment might be achieved, such as interfering with the binding of Aβ to EphB2, decreasing EphB2 degradation and increasing EphB2 expression. But before researchers in academia and the drug industry vigorously pursue this novel therapeutic mechanism, some cautionary notes are worth mentioning.
Given the complexity of this challenging subject, it is essential that these key findings be replicated. Moreover, which of the Alz heimer's disease models, if any, accurately reflects the human condition is debatable. As a result, whether EphB2 expression rectifies synaptic and memory deficits in other models of the disease should also be tested.
Alzheimer's disease affects several brain regions. So it is surprising that, in Cissé and colleagues' mice, expression of EphB2 in the dentate gyrus alone could completely overcome the memory deficits. As the authors suggest, improving the function of a subset of neurons may be sufficient to improve the performance of the larger networks in which they function. Nonetheless, it must be determined whether EphB2 can remedy the Aβ-induced deficits in other brain areas.
Finally, a key challenge is determining the time point during the progression of Alz heimer's disease at which administering a certain treatment would still be effective. Cissé et al. expressed EphB2 before any of the classic neuropathological features of Alzheimer's disease occurred. It should be determined whether expression of this receptor at later time points is equally effective.
Despite these caveats, this work opens up a new avenue of investigation into the pathogenic mechanisms of Alzheimer's disease, and points to a previously unknown mechanism that can be targeted for therapeutic purposes. It also offers hope to a research field that has recently suffered several highly publicized failed clinical trials. These findings
